Back to Search
Start Over
LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen.
- Source :
-
Annals of Oncology . 2022 Supplement 7, Vol. 33, pS1418-S1419. 2p. - Publication Year :
- 2022
- Subjects :
- *ATEZOLIZUMAB
*NON-small-cell lung carcinoma
*CANCER chemotherapy
*PATIENTS
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 159078753
- Full Text :
- https://doi.org/10.1016/j.annonc.2022.08.052